A Comparison of Plasmapheresis Methods in the Treatment of Late Antibody Mediated Rejection
Athena – Effect of Primary Immunosuppression on Development of De Novo Donor Specific Antibodies within First Year After Kidney Transplantation
Beyond Microarrays: Insights from Ncounter Transcript Analysis of Routine Archival Kidney Allograft Biopsies
Clazakizumab (clz, Anti-il-6 Antibody) Treatment Affects Il-6/il-6r Signaling by Increasing Soluble Gp130 (sgp130) in Hla-sensitized Kidney Transplant Patients (hs Ktx Pts) Treated for Chronic Antibody-mediated Rejection (cabmr)
Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
Digital Spatial Mrna Profiling Reveals Distinct Endothelial Transcripts in Dsa+ and Dsa- Endarteritis in Kidney Allografts
DSA Causes Mild Molecular ABMR-like Changes in Many Biopsies Not Diagnosed as Rejection
High Donor-Derived Cell-Free DNA Levels Predict Development of De Novo HLA Donor-Specific Antibodies After Kidney Transplantation – Data from the ADMIRAL Study
Higher Calcineurin Inhibitor Levels Associate with Graft Outcomes in Kidney Recipients with De Novo Donor-specific Antibodies of Either Hla Class I or II
Non-HLA Antibodies and Eplet Mismatches in Cases with Histological Picture of Antibody-Mediated Rejection with and without HLA Donor-Specific Antibodies
2021 American Transplant Congress